Pacific Biosciences Of California EBITDA Margin 2010-2024 | PACB
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Pacific Biosciences Of California (PACB) over the last 10 years. The current EBITDA margin for Pacific Biosciences Of California as of December 31, 2024 is .
| Pacific Biosciences Of California EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-12-31 |
$0.15B |
$-0.25B |
-161.69% |
| 2024-09-30 |
$0.17B |
$-0.28B |
-158.96% |
| 2024-06-30 |
$0.19B |
$-0.31B |
-161.38% |
| 2024-03-31 |
$0.20B |
$-0.31B |
-151.74% |
| 2023-12-31 |
$0.20B |
$-0.32B |
-159.70% |
| 2023-09-30 |
$0.17B |
$-0.33B |
-191.76% |
| 2023-06-30 |
$0.15B |
$-0.32B |
-216.44% |
| 2023-03-31 |
$0.13B |
$-0.31B |
-230.83% |
| 2022-12-31 |
$0.13B |
$-0.29B |
-228.35% |
| 2022-09-30 |
$0.14B |
$-0.27B |
-195.59% |
| 2022-06-30 |
$0.14B |
$-0.27B |
-190.65% |
| 2022-03-31 |
$0.14B |
$-0.24B |
-174.81% |
| 2021-12-31 |
$0.13B |
$-0.20B |
-148.85% |
| 2021-09-30 |
$0.12B |
$-0.16B |
-128.69% |
| 2021-06-30 |
$0.11B |
$-0.11B |
-102.83% |
| 2021-03-31 |
$0.09B |
$-0.10B |
-104.35% |
| 2020-12-31 |
$0.08B |
$-0.10B |
-120.25% |
| 2020-09-30 |
$0.08B |
$-0.09B |
-110.00% |
| 2020-06-30 |
$0.08B |
$-0.09B |
-109.64% |
| 2020-03-31 |
$0.09B |
$-0.09B |
-101.10% |
| 2019-12-31 |
$0.09B |
$-0.09B |
-98.90% |
| 2019-09-30 |
$0.08B |
$-0.10B |
-125.30% |
| 2019-06-30 |
$0.08B |
$-0.10B |
-129.11% |
| 2019-03-31 |
$0.08B |
$-0.10B |
-131.58% |
| 2018-12-31 |
$0.08B |
$-0.09B |
-118.99% |
| 2018-09-30 |
$0.08B |
$-0.08B |
-98.81% |
| 2018-06-30 |
$0.09B |
$-0.08B |
-87.78% |
| 2018-03-31 |
$0.09B |
$-0.08B |
-92.05% |
| 2017-12-31 |
$0.09B |
$-0.08B |
-84.04% |
| 2017-09-30 |
$0.10B |
$-0.08B |
-82.11% |
| 2017-06-30 |
$0.10B |
$-0.07B |
-77.08% |
| 2017-03-31 |
$0.10B |
$-0.07B |
-71.13% |
| 2016-12-31 |
$0.09B |
$-0.07B |
-72.53% |
| 2016-09-30 |
$0.10B |
$-0.05B |
-48.51% |
| 2016-06-30 |
$0.09B |
$-0.03B |
-33.33% |
| 2016-03-31 |
$0.09B |
$-0.02B |
-24.47% |
| 2015-12-31 |
$0.09B |
$-0.02B |
-25.81% |
| 2015-09-30 |
$0.07B |
$-0.04B |
-55.41% |
| 2015-06-30 |
$0.08B |
$-0.05B |
-64.20% |
| 2015-03-31 |
$0.07B |
$-0.06B |
-88.06% |
| 2014-12-31 |
$0.06B |
$-0.06B |
-95.08% |
| 2014-09-30 |
$0.05B |
$-0.06B |
-105.66% |
| 2014-06-30 |
$0.04B |
$-0.07B |
-171.79% |
| 2014-03-31 |
$0.03B |
$-0.07B |
-200.00% |
| 2013-12-31 |
$0.03B |
$-0.07B |
-250.00% |
| 2013-09-30 |
$0.03B |
$-0.08B |
-300.00% |
| 2013-06-30 |
$0.02B |
$-0.08B |
-371.43% |
| 2013-03-31 |
$0.02B |
$-0.08B |
-368.18% |
| 2012-12-31 |
$0.03B |
$-0.09B |
-338.46% |
| 2012-09-30 |
$0.03B |
$-0.09B |
-278.13% |
| 2012-06-30 |
$0.04B |
$-0.10B |
-240.00% |
| 2012-03-31 |
$0.04B |
$-0.10B |
-218.18% |
| 2011-12-31 |
$0.03B |
$-0.10B |
-302.94% |
| 2011-09-30 |
$0.02B |
$-0.12B |
-531.82% |
| 2011-06-30 |
$0.01B |
$-0.13B |
-1163.64% |
| 2011-03-31 |
$0.00B |
$-0.14B |
-13800.00% |
| 2010-12-31 |
$0.00B |
$-0.13B |
-6700.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED INSTRUMENTS |
$0.333B |
$0.154B |
|
Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time (SMRT) technology. SMRT generates long reads that help in assembling a whole human genome from scratch, without using an existing reference genome as a template. This process is known as de novo assembly. To observe DNA replication process smoothly, PacBio offers the SMRT Cell, Phospholinked nucleotides and The PacBio RS II System. The PacBio RS II System includes the PacBio RS II instrument, consumables and software. PacBio launched its new Sequel system based on SMRT technology. PacBio deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency was resolved.
|
